Attached files
| file | filename |
|---|---|
| EX-23.2 - EX-23.2 - NRX Pharmaceuticals, Inc. | d175615dex232.htm |
| EX-5.1 - EX-5.1 - NRX Pharmaceuticals, Inc. | d175615dex51.htm |
| S-1/A - S-1/A - NRX Pharmaceuticals, Inc. | d175615ds1a.htm |
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the inclusion in this Registration Statement of NRx Pharmaceuticals, Inc. on Form S-1 of our report dated April 1, 2021, except for the effects of the restatement discussed in Note 2 as to which the date is May 11, 2021, with respect to our audits of the financial statements of Big Rock Partners Acquisition Corp. as of December 31, 2020 and 2019 and for each of the two years in the period ended December 31, 2020, which report appears in the prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such prospectus.
/s/ Marcum LLP
Marcum LLP
San Francisco, CA
July 6, 2021